Nice support level at $20 Filled Gap up and Gap down. If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels. CRISPR got upgraded.
EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally.
Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.